Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers

NCT ID NCT07705334

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. Participants take the drug once daily in 21-day cycles until their disease worsens or side effects become unacceptable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental oral drug called SHY-ONC6
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early, first-in-human trial with only 30 participants, so safety and effectiveness are not yet known. Many early-stage cancer drugs do not advance to later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • NEXT Oncology

    RECRUITING

    San Antonio, Texas, 78229, United States

    Contact

  • SCRI at HCA HealthONE

    NOT_YET_RECRUITING

    Denver, Colorado, 80218, United States

    Contact

  • The University of Texas MD Anderson Cancer Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.